EGFR and non-small cell lung carcinoma: From 2021 onwards, the indication of multiple pre-existing molecules has been extended to the (neo)adjuvant setting; these include three ICIs for patients with high risk of recurrence [13,32,33,34,35,36,37,38] and one TKI for patients with EGFR-mutated NSCLC [13,39].